China’s New Legal Power To Limit Or Block Mergers Could Signal Challenges For Global Pharmaceutical Alliances
This article was originally published in The Pink Sheet Daily
Executive Summary
Armed with a new antitrust law, the Ministry of Commerce could derail megamergers of companies with an interest in China, like Pfizer/Wyeth, slated to be completed later this year.
You may also be interested in...
Pfizer’s New Org Chart Brings Eight Wyeth Execs Topside
In a move designed to allay concerns about post-Wyeth integration challenges, Pfizer outlined on April 7 the leadership structure of the future entity
68 Billon Dollar Question: Could China's Government Block Worldwide Merger Of Wyeth And Pfizer?
BEIJING - Tucked away toward the end of the $68-billion merger agreement between Pfizer Inc. and Wyeth is a clause that could give the Chinese government the ultimate power to approve or block this worldwide union of American pharmaceutical giants
In Wake Of Heparin Deaths, FDA Set To Launch Pilot Project Aimed At Preventing Imports Of Adulterated Drugs
BEIJING - One year after adulterated heparin sourced from China began triggering scores of adverse reactions and deaths in U.S. patients, U.S. FDA is preparing to launch a voluntary pilot program aimed at helping prevent contaminated drugs from entering the country